Parabilis Medicines, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mathai Mammen
- Full Time Employees
- 145
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 30 Acorn Park Dr Cambridge MA United States of America 02140
- IPO Date
- Jun 10, 2026
- CIK
- 0001657677
- Website
- parabilismed.com
- Similar Companies
- Business
- Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative Helicon peptide therapeutics for cancer and other diseases. Through its Helicon platform, Parabilis designs ultra-tunable, stabilized helical peptides to target historically undruggable intracellular proteins, with FOG-001 (zolucatetide) as the lead program, a first-in-class β-catenin–TCF inhibitor evaluated in multiple solid tumor indications. The company operates primarily in the United States, with headquarters in Cambridge, Massachusetts, and maintains a pipeline that includes additional preclinical programs and targeted degraders. Parabilis emphasizes collaborations to advance its portfolio, including strategic research and development partnerships, while pursuing financing to support its clinical development efforts and potential future product expansions. Founding year and corporate headquarters are noted as part of its standard data profile, along with ongoing clinical and preclinical activities across rare and common tumor indications. The company continues to expand its translational capabilities and seek opportunities to broaden its therapeutic reach through partnerships, trials, and selective commercialization strategies.
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
Parabilis Medicines aims to raise $633 million in upsized US IPO